KDEV Karolinska Development AB

Karolinska Development Annual Report 2024 published

Karolinska Development Annual Report 2024 published

STOCKHOLM, SWEDEN – March 21, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces publication of its Annual Report 2024.

The report is now available to download at

For further information, please contact:

Viktor Drvota, CEO, Karolinska Development AB

Phone: 2, e-mail:

Hans-Christoffer “HC” Toll, CFO, Karolinska Development AB

Phone: +46 70 717 00 41, e-mail:

TO THE EDITORS

About Karolinska Development AB



Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.

Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.

Karolinska Development has a portfolio of eleven companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.

The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.

For more information, please visit

Attachments



EN
21/03/2025

Underlying

KDEVKarolinska Development AB

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Karolinska Development AB

 PRESS RELEASE
Free
KDEV Karolinska Deve...

Karolinska Development’s portfolio company Umecrine Cognition raises M...

Karolinska Development’s portfolio company Umecrine Cognition raises MSEK 24.6 for the ongoing clinical development of golexanolone STOCKHOLM, SWEDEN – July 14, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that the portfolio company Umecrine Cognition has raised SEK 24.6 million through a convertible loan to be used for the ongoing clinical Phase 1b/2a study of golexanolone in primary biliary cholangitis. The convertible loan with attached share options is directed to a consortium of existing long-term shareholders and investors in Umecrine Cognition, including K...

July 14, 2025 1 EN
 PRESS RELEASE
Free
KDEV Karolinska Deve...

Karolinska Developments portföljbolag Umecrine Cognition säkrar SEK 24...

Karolinska Developments portföljbolag Umecrine Cognition säkrar SEK 24,6 miljoner till den pågående kliniska utvecklingen av golexanolon STOCKHOLM, 14 juli 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget Umecrine Cognition har genomfört en kapitalanskaffning om SEK 24,6 miljoner genom ett konvertibellån som ska användas till den pågående kliniska fas 1b/2a-studien med golexanolon inom primär biliär kolangit. Konvertibellånet med tillhörande optioner är riktat till ett investerarkonsortium med befintliga, långsiktiga ägare och investerare i Umecrine Cogn...

July 14, 2025 1 EN
 PRESS RELEASE
Free
KDEV Karolinska Deve...

Karolinska Development's portfolio company Modus Therapeutics complete...

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in part 1 of its phase 2a study with sevuparin STOCKHOLM, SWEDEN July 14, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Modus Therapeutics has completed patient enrollment on schedule to part 1 of its ongoing clinical phase 2a study with sevuparin, which is being evaluated as a treatment for patients with chronic kidney disease with anemia. Modus Therapeutics, listed on Nasdaq First North Growth Market, has successfully completed the patient enrollment fo...

July 14, 2025 1 EN
 PRESS RELEASE
Free
KDEV Karolinska Deve...

Karolinska Developments portföljbolag Modus Therapeutics har slutfört ...

Karolinska Developments portföljbolag Modus Therapeutics har slutfört rekryteringen i del 1 av sin fas 2a-studie med sevuparin STOCKHOLM, SVERIGE 14 juli 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget Modus Therapeutics har slutfört patientrekryteringen enligt tidsplan till del 1 av sin pågående kliniska fas 2a-studie med läkemedelskandidaten sevuparin, som utvärderas som en behandling för patienter med kronisk njursjukdom med anemi. Modus Therapeutics, noterat på Nasdaq First North Growth Market, har framgångsrikt slutfört patientrekryteringen t...

July 14, 2025 1 EN
 PRESS RELEASE
Free
KDEV Karolinska Deve...

Karolinska Development receives update from Organon concerning OG-6219

Karolinska Development receives update from Organon concerning OG-6219 STOCKHOLM, SWEDEN – July 3, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces an update from Organon on the development of the drug candidate OG-6219, acquired by Organon through its acquisition of Forendo Pharma in 2021. Following results from a Phase 2 clinical study with OG-6219, Organon plans to discontinue the clinical development of the drug candidate. Organon has announced results from the Phase 2 ELENA proof-of-concept, where the drug candidate OG-6219 was evaluated in patients with endom...

July 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch